Parexel

Parexel Completes ClinPhone Acquisition and Cuts Earnings Guidance

Tuesday, September 9, 2008 09:41 AM

Parexel, a global contract research organization (CRO), cut its earnings guidance for its first quarter of fiscal year 2009 and for the full fiscal year, with the successful completion of its acquisition of eClinical trial technology company ClinPhone for about $182 million.

More... »

Parexel Finalizes ClinPhone Acquisition

Thursday, August 14, 2008 02:56 PM

Contract research organization (CRO) Parexel International has finalized the acquisition of UK-based clinical technology firm ClinPhone. ClinPhone and Perceptive Informatics, Parexel’s existing technology subsidiary, will combine to provide enhanced eClinical services and products, according to a Parexel statement released today.

More... »

Parexel's 4Q Revenues Jump 33%

Thursday, August 7, 2008 09:01 AM

Another of the top global contract research organizations (CROs), Parexel reported strong fourth quarter revenues after the bell Wednesday, rising 32.6% to a record $272.2 million compared with $205.2 million in the prior year period.

More... »

eResearchTechnology Names CFO

Thursday, July 31, 2008 08:07 AM

eResearchTechnology (eRT), a provider of centralized ECG and eClinical technology, ePRO and other services to the biotech, pharmaceutical and medical device industries, appointed Keith Schneck as executive vice president and chief financial officer.

More... »

Sponsors Look to CROs for Phase I Consulting

Monday, July 28, 2008 08:16 AM

Although many boutique consulting firms and the majority of contract research organizations (CROs) have been offering trial design and regulatory consulting for years, demand has been surfacing as of late in phase I.

More... »

Medidata Aspiring to Win Over CRO Market

Tuesday, July 8, 2008 06:05 AM

As the industry enters a period of eClinical consolidation — ClinPhone and Datalabs, PharmaLinkFHI and Matrix Contract Research, Parexel and Green Mountain Logic — and as the adoption of these technologies swells, not only has the playing field narrowed for these companies, but the game itself is changing.

More... »

Quintiles Will Not Pursue ClinPhone Acquisition, Parexel’s Offer Stands

Wednesday, July 2, 2008 12:47 PM

Durham, N.C.-based contract research organization (CRO) Quintiles stated it will not counter Waltham, Mass.-based rival CRO Parexel’s bid for the acquisition of ClinPhone, a clinical technology company based in the UK. Parexel’s offer is $182 million in cash, an 86% premium over ClinPhone's share price.

More... »

Perceptive Informatics Boosts Cardiac Imaging Capabilities With DigiView Integration

Friday, June 6, 2008 01:58 PM

Waltham, Mass.-based Perceptive Informatics, Parexel’s clinical technology subsidiary, teamed up with imaging software company Digisonics in a platform integration effort involving DigiView — Perceptive’s cardiac function assessment tool. The system allows for electronic review, analysis, reporting, and archiving of medical images related to cardiac function assessment. Perceptive stated the platform exceeds HIPAA security requirements and can generate an audit trail for regulatory purposes.

More... »

A Stock Split Can Make You Forget

Wednesday, February 15, 2006 11:06 AM

PPD's two-for-one stock split is good news for the top global clinical  research organizations. Investors attracted to the sector by the  company's split announcement Feb. 8 can focus on PPD and other top CROs  rather than the sideshow embattled SFBC has become. When new investors look at top CROs such as PPD, Quintiles , PRA, ICON, Parexel and Covance, they will see the pharmaceutical outsourcing industry  ready to consolidate around a handful or so of these companies.These  global CROs have a big advantage over the estimated 1,000 other small  CROs throughout the world. They have international infrastructure in  place to conduct complex clinical trials in thousands of patients at  sites across multiple countries.That global presence is not easy to  build and represents a barrier to entry for small CROs trying to roll  up into a global player.

More... »

What's In A Name? A Fresh Start, Maybe

Friday, February 3, 2006 02:09 PM

A new CEO and a change of scenery are good first steps to righting the ship at SFBC. A new name could also do the embattled contract research organization some good. Something like, say, PharmaNet? Two weeks ago Jeffrey McMullen assumed the role of CEO. He joined SFBC as part of the company’s December 2004 acquisition of CRO PharmaNet for $245 million in cash. By our measures, the PharmaNet name has a lot of positive brand equity. It has been a top performer in the Thomson CenterWatch Survey of Investigative Sites in the US in 2005 and 2003. It was also top-rated in Europe in 2004. That’s high praise from our survey respondents – principal investigators and study coordinators – who are on the front lines of clinical research.

More... »